QiShenYiQi Pill Ameliorates Cardiac Fibrosis After Pressure Overload-Induced Cardiac Hypertrophy by Regulating FHL2 and the Macrophage RP S19/TGF-β1 Signaling Pathway

Purpose: Heart failure (HF) is a leading cause of morbidity and mortality worldwide, and it is characterized by cardiac hypertrophy and fibrosis. However, effective treatments are not available to block cardiac fibrosis after cardiac hypertrophy. The QiShenYiQi pill (QSYQ) is an effective treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Anwaier, Gulinigaer, Xie, Ting-Ting, Pan, Chun-Shui, Li, An-Qing, Yan, Li, Wang, Di, Chen, Fan-Kai, Weng, Ding-Zhou, Sun, Kai, Chang, Xin, Fan, Jing-Yu, Han, Jing-Yan, Liu, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326396/
https://www.ncbi.nlm.nih.gov/pubmed/35910357
http://dx.doi.org/10.3389/fphar.2022.918335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326396/
https://www.ncbi.nlm.nih.gov/pubmed/35910357
http://dx.doi.org/10.3389/fphar.2022.918335

Ejemplares similares